China-based Hutchmed failed to get the U.S. Food and Drug Administration’s approval for the company’s proposed drug for pancreatic cancer.
Apotex Corp. announced April 12 the company’s release of Paclitaxel protein-bound particles for injection (albumin-bound), a generic version of Abraxane in the United States.
ImmunityBio shared interim results from the company’s ongoing metastatic pancreatic cancer trial, demonstrating overall survival that is double the historical rate.
Cranbury, New Jersey-based Rafael Pharmaceuticals reported disappointing results from two Phase III clinical trials evaluating the safety and efficacy of the cancer metabolism drug CPI-613 (devimistat) when combined with modified FOLFIRINOX (mFFX) as a first-line therapy.
Pancreatic cancer has the lowest survival rate of the most common cancers as less than 10 percent of patients survive longer than five years, largely due to most cases being diagnosed at a late stage. A collaboration between NovoCure and Roche hopes to improve those odds.
Stephen Byers, Ph.D., associate director and professor of oncology at Georgetown Lombardi, and his team published a paper in the journal Gastroenterology regarding their findings of a novel target for pancreatic cancer therapy.
The U.S. Food and Drug Administration placed a clinical hold on patient enrollment and dosing in an early-stage trial of the Bellicum Pharmaceuticals’ cancer treatment BPX-601, after the death of a patient.
A dual treatment approach consisting of gemcitabine combined with AB Science’s highly selective tyrosine kinase inhibitor masitinib was associated with significant increases in survival among patients with pancreatic cancer and pain, according to recently announced results from a confirmatory Phase III study.
Paris-based Ipsen secured Fast Track designation from the U.S. Food and Drug Administration for Onivyde (irinotecan liposome injection) for study patients with small cell lung cancer (SCLC) who progressed following a first-line platinum-based regimen.
A study published in the Nov. 2 edition of Cell suggests that pancreatic cancer cells avoid starvation by signaling to nerves, which encourages them to grow into dense tumors and release the nutrients the cells need to survive.